Literature DB >> 29268470

Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?

Kenichi Suda1,2.   

Abstract

Entities:  

Year:  2017        PMID: 29268470      PMCID: PMC5720976          DOI: 10.21037/jtd.2017.10.15

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

3.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

Review 4.  Scientific Advances in Thoracic Oncology 2016.

Authors:  Ross A Soo; Emily C A Stone; K Michael Cummings; James R Jett; John K Field; Harry J M Groen; James L Mulshine; Yasushi Yatabe; Lukas Bubendorf; Sanja Dacic; Ramon Rami-Porta; Frank C Detterbeck; Eric Lim; Hisao Asamura; Jessica Donington; Heather A Wakelee; Yi-Long Wu; Kristin Higgins; Suresh Senan; Benjamin Solomon; Dong-Wan Kim; Melissa Johnson; James C H Yang; Lecia V Sequist; Alice T Shaw; Myung-Ju Ahn; Daniel B Costa; Jyoti D Patel; Leora Horn; Scott Gettinger; Solange Peters; Murry W Wynes; Corinne Faivre-Finn; Charles M Rudin; Anne Tsao; Paul Baas; Ronan J Kelly; Natasha B Leighl; Giorgio V Scagliotti; David R Gandara; Fred R Hirsch; David R Spigel
Journal:  J Thorac Oncol       Date:  2017-06-01       Impact factor: 15.609

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 6.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Authors:  Audrey Mansuet-Lupo; Marco Alifano; Nicolas Pécuchet; Jérôme Biton; Etienne Becht; Jeremy Goc; Claire Germain; Hanane Ouakrim; Jean-François Régnard; Isabelle Cremer; Pierre Laurent-Puig; Marie-Caroline Dieu-Nosjean; Hélène Blons; Diane Damotte
Journal:  Am J Respir Crit Care Med       Date:  2016-12-01       Impact factor: 21.405

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

10.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

View more
  3 in total

1.  Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.

Authors:  Dragana Jovanovic; Marina Roksandic Milenkovic; Jelena Kotur Stevuljevic; Jelena Markovic; Vesna Ceriman; Milica Kontic; Vesna Skodric Trifunovic
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

2.  TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.

Authors:  Daniel R Principe; Alex Park; Matthew J Dorman; Sandeep Kumar; Navin Viswakarma; Jonathan Rubin; Carolina Torres; Ronald McKinney; Hidayatullah G Munshi; Paul J Grippo; Ajay Rana
Journal:  Mol Cancer Ther       Date:  2018-12-26       Impact factor: 6.009

3.  Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway.

Authors:  Dongwei Dou; Xiaoyang Ren; Mingli Han; Xiaodong Xu; Xin Ge; Yuanting Gu; Xinxing Wang
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.